Ceftobiprole for the treatment of pneumonia

C. Cillóniz, C. Dominedò, C. Garcia-Vidal, A. Torres

Producción científica: Artículo CientíficoArtículo de revisiónrevisión exhaustiva

11 Citas (Scopus)


Ceftobiprole is a fifth-generation cephalosporin with potent antimicrobial activity against Gram positive and Gram-negative bacteria. It has been approved in major European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Ceftobiprole is currently in a phase 3 clinical program for registration in the U.S. In 2015, it was designated as an infectious disease product qualified for the treatment of lung and skin infections by the FDA. The efficacy of ceftobiprole in pneumonia has been demonstrated in two-phase III clinical trials conducted in patients with CAP and HAP. The recommended dose in the adult with pneumonia is 500 mg every 8 h infused in 2 h; in case of renal failure, the regimen of administration must be adjusted according to the patient's renal function. It is not necessary to adjust the dose according to gender, age, body weight or liver failure. In case of hyperfiltration, an extension to 4 h infusion of the 500mg TID is required.

Idioma originalInglés estadounidense
Páginas (desde-hasta)17-23
PublicaciónRevista Espanola de Quimioterapia
EstadoIndizado - 1 set. 2019


Profundice en los temas de investigación de 'Ceftobiprole for the treatment of pneumonia'. En conjunto forman una huella única.

Citar esto